Vertex Pharmaceuticals (VRTX) Income from Continuing Operations (2009 - 2026)

Vertex Pharmaceuticals' Income from Continuing Operations history runs 18 years deep, the most recent figure standing at 1031400000.0 for Q1 2026.

• In Q1 2026, Income from Continuing Operations rose 59.59% year-over-year to 1031400000.0; the TTM figure through Mar 2026 stood at 4338300000.0 (up 538.7% YoY), while the FY2025 annual figure was 3953200000.0, up 838.09% from the prior year.
• Income from Continuing Operations was 1031400000.0 for Q1 2026 at Vertex Pharmaceuticals, down from 1191100000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 1191100000.0 in Q4 2025 to a low of 3593600000.0 in Q2 2024.
• Historically, Income from Continuing Operations has averaged 670035294.12 across 5 years, with a median of 930500000.0 in 2022.
• The sharpest annual moves came in 2022 and 2024: Income from Continuing Operations jumped 1109.7% in 2022, then tumbled 492.44% in 2024.
• A 5-year view of Income from Continuing Operations shows it stood at 818900000.0 in 2022, then increased by 18.31% to 968800000.0 in 2023, then decreased by 5.76% to 913000000.0 in 2024, then jumped by 30.46% to 1191100000.0 in 2025, then decreased by 13.41% to 1031400000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 1031400000.0 (Q1 2026), 1191100000.0 (Q4 2025), and 1082900000.0 (Q3 2025), per Business Quant data.